Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Alzheimers Care / Current Research Opportunities
 

Current Research Opportunities

Multicultural

Please note: recent developments related to COVID-19 have placed in-person screening and enrollment visits for current clinical trial studies in AD-CARE on hold until further notice.  

 If you are still interested in participating in an Alzheimer’s disease study, learn more about what you can do now from your home:

 

Alzheimer Prevention Trials (APT) Webstudy

 

If you are 50 years of age or older, you can monitor your own cognitive health by participating in the Alzheimer Prevention Trials (APT) Webstudy.  The APT Webstudy is designed to identify people who may have an increased risk for developing Alzheimer’s disease, using the latest technology to monitor their cognitive performance through regular online memory testing.  Volunteers of the APT Webstudy participate at their convenience, anywhere they have access to the internet.  APT Webstudy participants benefit by:

  • Having their cognitive health assessed over time;
  • Being on the ‘fast track’ for relevant clinical trials to prevent Alzheimer’s;
  • Making an invaluable contribution to advancing Alzheimer’s research, perhaps helping those in the research field find the first Alzheimer’s survivor; and
  • Helping ensure that future generations do not experience Alzheimer’s and its difficult challenges.

 

Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD)

 

Those identified to have a potential increased risk for memory loss caused by Alzheimer’s disease, will be referred from the APT Webstudy to the Trial Ready Cohort for the Prevention of Alzheimer’s Dementia (TRC-PAD) In-person study.  The purpose of TRC-PAD is to find as many people as possible (also called a “cohort”) who are interested in participating in clinical trials aimed at discovering treatments that will reduce the risk of developing Alzheimer’s dementia. TRC-PAD will help researchers enroll participants into these trials quickly to allow new treatments to be discovered as soon as possible.  Participants do not have to participate in the TRC-PAD study in order to participate in the online APT Webstudy.

To participate in the APT Webstudy or to learn more, please visit www.aptwebstudy.org  

                                                                   

__________________________________________________________________________

Active studies; currently on hold for visits until further notice: 

 

ADNI – 3

Supported by the Northern California Institute for Research and Education (NCRIE) with the Alzheimer’s Therapeutic Research Institute (ATRI) through a grant from the National Institute on Aging (NIA), ADNI (Alzheimer’s Disease Neuroimaging Initiative) looks at the relationship between clinical, cognitive, imaging, genetic, and biomarker tests to better understand the full spectrum of Alzheimer’s disease. The data from this study will be used in the development of future research studies that will focus on the treatment of AD.         

 https://clinicaltrials.gov/ct2/show/NCT02854033

                                                                                                                                                                                                                                                                                                

Clarity AD

Sponsored by Eisai Inc., in collaboration with Biogen Inc., this study assesses safety, tolerability, and efficacy of an experimental medication (BAN2401) in people with early Alzheimer’s disease.

https://clinicaltrials.gov/ct2/show/NCT03887455

 

 

S-CitADSample Processing

Funded by the National Institute on Aging (NIA), this study assesses the antidepressant escitalopram, in addition to psychosocial intervention, for the treatment of agitation in people with Alzheimer’s disease.

 https://clinicaltrials.gov/ct2/show/NCT03108846

                                                                                           

__________________________________________________________________________

 

Active studies; not open for enrollment: 

 

A4

(Anti-Amyloid Treatment in Asymptomatic Alzheimer's study)
 

Conducted by the Alzheimer’s Therapeutic Research Institute (ATRI) in conjunction with Eli Lilly and Company, through a grant from the National Institute on Aging (NIA), this research study focuses on whether a new investigational medication (solanezumab) can slow the progression of memory problems associated with Alzheimer’s disease.

 https://clinicaltrials.gov/ct2/show/NCT02008357

 

ADMET – II

(Apathy in Dementia Methylphenidate Trial 2)

Sponsored by the National Institute on Aging (NIA), this research study examines the safety and effectiveness of an ADHD medication (methylphenidate) to treat clinically significant apathy in those with Alzheimer’s disease.

 https://clinicaltrials.gov/ct2/show/NCT02346201

 

ADNI – DoD

Sponsored by the Department of Defense, this research study examines brain aging in Vietnam War Veterans as it correlates to Traumatic Brain Injury (TBI) and Post-Traumatic Stress Disorder (PTSD) that may be associated with a greater risk of Alzheimer’s disease.

 https://clinicaltrials.gov/ct2/show/NCT01687153?term=DOD&cond=Alzheimer+Disease&cntry=US&draw=2&rank=1

 

GRADUATE II

Sponsored by Hoffman-La Roche Pharmaceuticals, this study evaluates the efficacy and safety of an investigational medication (gantenerumab) in those with early/mild Alzheimer's disease.

https://clinicaltrials.gov/ct2/show/NCT03443973?term=roche&cond=Alzheimer+Disease&cntry=US&state=US%3ANY&city=Rochester&draw=1&rank=1

 

Lauriet

Sponsored by Genentech, a member of the Roche Group, this research study evaluates the efficacy and safety of an investigational medication (MTAU9937A) in those with moderate Alzheimer’s disease. 

https://clinicaltrials.gov/ct2/show/NCT03828747

 

 

LEARN

Conducted by the Alzheimer’s Therapeutic Research Institute (ATRI) through a grant from the Alzheimer’s Association, and the National Institute on Aging (NIA), this observational study is a companion study to the A4 Trial to evaluate the rate of cognitive change in older adults that do not have elevated levels of brain amyloid.

https://clinicaltrials.gov/ct2/show/NCT02488720

 

 

TANGO

Sponsored by Biogen Pharmaceuticals, this study evaluates the safety and tolerability of an investigational medicine (BIIB092) in participants with mild to moderate Alzheimer’s disease.

https://clinicaltrials.gov/ct2/show/NCT03352557?term=tango&cond=Alzheimer+Disease&rank=2

 

 

TAURIEL

Sponsored by Genentech, a member of the Roche Group, this study assesses safety, tolerability, and efficacy of an experimental medication (MTAU9937A) in people with early to mild signs of Alzheimer’s disease.

https://clinicaltrials.gov/ct2/show/study/NCT03289143?term=genentech&cond=Alzheimer+Disease&rank=2&show_locs=Y#locn

 

 

T2 Protect AD

Sponsored by Biohaven Pharmaceuticals, in conjunction with the Alzheimer's Disease Cooperative Study (ADCS), this study assesses safety, tolerability, and efficacy of an experimental medication (Troriluzole, BHV-4157) in people with mild to moderate Alzheimer’s Disease.

https://clinicaltrials.gov/ct2/show/NCT03605667?recrs=abd&cond=Alzheimer+Disease&cntry=US&state=US%3ANY&city=rochester&draw=2&rank=6

 

__________________________________________________________________________

For more information, or to sign up for a study, please visit: https://www.alz.org/research/clinical_trials/find_clinical_trials_trialmatch.asp